# Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)

> **NCT00557791** · PHASE3 · WITHDRAWN · sponsor: **OPKO Health, Inc.**

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** Bevasiranib
- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT00557791
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-11
- **Primary completion:** 2011-07
- **Final completion:** 2012-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never initiated
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00557791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00557791, "Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00557791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*